Clinical Scorecard: Therapeutic Focus: Talkin’ Bout Regeneration
At a Glance
| Category | Detail |
|---|---|
| Condition | Dry Eye Disease (DED), Superficial Punctate Keratitis, Stage 1 Neurotrophic Keratitis |
| Key Mechanisms | Anti-inflammatory, anti-scarring, and antiangiogenic actions |
| Target Population | Patients with mild-to-moderate dry eye disease and neurotrophic keratitis |
| Care Setting | Ophthalmology practices |
Key Highlights
- CAM360 AmnioGraft (CAM360 AG) shows significant healing properties.
- Benefits of treatment last between 3 to 6 months.
- Improvement in corneal sensitivity observed after a single 24-hour treatment.
- Patient comfort enhanced due to adhesive properties and reduced treatment time.
- Convenient for working-age patients with a quick application process.
Guideline-Based Recommendations
Diagnosis
- Assess corneal sensitivity and ocular surface health in patients with DED.
Management
- Utilize CAM360 AG for treating DED and neurotrophic keratitis.
Monitoring & Follow-up
- Evaluate patient outcomes and corneal sensitivity at follow-up visits.
Risks
- Consider individual patient factors such as blink strength and eyelid position.
Patient & Prescribing Data
Patients with moderate-to-severe dry eye disease and neurotrophic keratitis.
CAM360 AG provides a quick reset to the cornea with minimal downtime.
Clinical Best Practices
- Prepare the membrane and collagen shield complex in a separate room for efficiency.
- Be adaptable in treatment methodologies based on patient-specific needs.
References
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
